<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2024.1395815</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Unraveling the potential of graphene quantum dots against <italic>Mycobacterium tuberculosis</italic> infection</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Santarelli</surname> <given-names>Giulia</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1751331/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Perini</surname> <given-names>Giordano</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/976859/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Salustri</surname> <given-names>Alessandro</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Palucci</surname> <given-names>Ivana</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/422825/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Rosato</surname> <given-names>Roberto</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Palmieri</surname> <given-names>Valentina</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1876443/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Iacovelli</surname> <given-names>Camilla</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Bellesi</surname> <given-names>Silvia</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1290920/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Sali</surname> <given-names>Michela</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Sanguinetti</surname> <given-names>Maurizio</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/193630/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name><surname>De Spirito</surname> <given-names>Marco</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/960002/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Papi</surname> <given-names>Massimiliano</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/907246/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>Delogu</surname> <given-names>Giovanni</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/193507/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name><surname>De Maio</surname> <given-names>Flavio</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="author-notes" rid="fn0001"><sup>&#x2020;</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie-Sezione di Microbiologia, Universit&#x00E0; Cattolica del Sacro Cuore</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff>
<aff id="aff2"><sup>2</sup><institution>Dipartimento di Neuroscienze, Universit&#x00E0; Cattolica del Sacro Cuore</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff>
<aff id="aff3"><sup>3</sup><institution>Fondazione Policlinico Universitario &#x201C;A. Gemelli&#x201D;</institution>, <addr-line>IRCCS, Rome</addr-line>, <country>Italy</country></aff>
<aff id="aff4"><sup>4</sup><institution>Istituto dei Sistemi Complessi, CNR</institution>, <addr-line>Rome</addr-line>, <country>Italy</country></aff>
<aff id="aff5"><sup>5</sup><institution>Mater Olbia Hospital</institution>, <addr-line>Olbia</addr-line>, <country>Italy</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0002">
<p>Edited by: Robert Jansen, Radboud University, Netherlands</p>
</fn>
<fn fn-type="edited-by" id="fn0003">
<p>Reviewed by: Johid Malik, University of Nebraska Medical Center, United States</p>
<p>Moiz Ansari, Texas A&#x0026;M University, United States</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Massimiliano Papi, <email>massimiliano.papi@unicatt.it</email></corresp>
<fn fn-type="equal" id="fn0001">
<p><sup>&#x2020;</sup>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1395815</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>03</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>04</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2024 Santarelli, Perini, Salustri, Palucci, Rosato, Palmieri, Iacovelli, Bellesi, Sali, Sanguinetti, De Spirito, Papi, Delogu and De Maio.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Santarelli, Perini, Salustri, Palucci, Rosato, Palmieri, Iacovelli, Bellesi, Sali, Sanguinetti, De Spirito, Papi, Delogu and De Maio</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>The emergence of drug-resistant <italic>Mycobacterium tuberculosis (Mtb)</italic> strains has underscored the urgent need for novel therapeutic approaches. Carbon-based nanomaterials, such as graphene oxide (GO), have shown potential in anti-TB activities but suffer from significant toxicity issues.</p>
</sec>
<sec>
<title>Methods</title>
<p>This study explores the anti-TB potential of differently functionalized graphene quantum dots (GQDs) &#x2013; non-functionalized, L-GQDs, aminated (NH<sub>2</sub>-GQDs), and carboxylated (COOH-GQDs) &#x2013; alone and in combination with standard TB drugs (isoniazid, amikacin, and linezolid). Their effects were assessed in both axenic cultures and <italic>in vitro</italic> infection models.</p>
</sec>
<sec>
<title>Results</title>
<p>GQDs alone did not demonstrate direct mycobactericidal effects nor trapping activity. However, the combination of NH<sub>2</sub>-GQDs with amikacin significantly reduced CFUs in <italic>in vitro</italic> models. NH<sub>2</sub>-GQDs and COOH-GQDs also enhanced the antimicrobial activity of amikacin in infected macrophages, although L-GQDs and COOH-GQDs alone showed no significant activity.</p>
</sec>
<sec>
<title>Discussion</title>
<p>The results suggest that specific types of GQDs, particularly NH<sub>2</sub>-GQDs, can enhance the efficacy of existing anti-TB drugs. These nanoparticles might serve as effective adjuvants in anti-TB therapy by boosting drug performance and reducing bacterial counts in host cells, highlighting their potential as part of advanced drug delivery systems in tuberculosis treatment. Further investigations are needed to better understand their mechanisms and optimize their use in clinical settings.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Graphene Quantum Dots (GQDs)</kwd>
<kwd><italic>Mycobacterium tuberculosis (Mtb)</italic></kwd>
<kwd>anti-tuberculosis therapy</kwd>
<kwd>drug resistance</kwd>
<kwd>nanoparticle adjuvants</kwd>
</kwd-group>
<counts>
<fig-count count="7"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="51"/>
<page-count count="14"/>
<word-count count="8425"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Microbial Symbioses</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<title>Introduction</title>
<p>Tuberculosis (TB) remains a major global health concern, being one of the leading causes of death from a single infectious agent (<xref ref-type="bibr" rid="ref48">World Health Organization, 2022</xref>). The disease is cured with a multidrug pharmacological treatment, consisting of daily dosing of a four-drug regimen, for a period ranging from 4 to 8&#x2009;months or longer (<xref ref-type="bibr" rid="ref43">Timothy, 2022</xref>). The emergence of multidrug resistant and extensively drug resistant <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>) strains makes the identification of novel potential treatment strategies a priority. The search for new solutions includes the investigation of both novel agents and repurposing approved drugs with potential anti-mycobacterial effects (<xref ref-type="bibr" rid="ref26">Palucci and Delogu, 2018</xref>; <xref ref-type="bibr" rid="ref2">Battah et al., 2019</xref>; <xref ref-type="bibr" rid="ref7">De Maio et al., 2022</xref>).</p>
<p>Carbon-based Nanomaterials (CNM) treatments, particularly Graphene-Oxide (GO) have showed a promising activity against mycobacteria (<xref ref-type="bibr" rid="ref10">De Maio et al., 2019</xref>). Even though GO did not show a direct bactericidal activity, it was able to entrap mycobacteria in a net thus interfering with the normal infection of macrophages (<xref ref-type="bibr" rid="ref11">De Maio et al., 2019</xref>). Furthermore, co-administration of GO with linezolid, a second line anti-TB drug, resulted in a synergistic anti-<italic>Mtb</italic> effect, due also to the increase of reactive oxygen species (ROS) production (<xref ref-type="bibr" rid="ref12">De Maio et al., 2020</xref>). However, interaction of GO sheets with isoniazid or amikacin interfered and hindered antibiotic activity (<xref ref-type="bibr" rid="ref12">De Maio et al., 2020</xref>). Moreover, when GO was used in a <italic>Mtb</italic> infection model based on peripheral blood mononuclear cells, we observed a failure in controlling mycobacterial replication, largely due to the toxicity of GO against monocytes and CD4 T cells (<xref ref-type="bibr" rid="ref41">Salustri et al., 2023</xref>).</p>
<p>Among CNMs with size less than 100&#x2009;nm, Graphene quantum dots (GQDs) and carbon quantum dots (CQDs) represent two distinct classes of nanomaterials with unique structural and functional attributes. GQDs are monolayer or few-layer structures filled with various oxygen-containing functional groups like hydroxyl, epoxy, and carboxyl. These functional groups not only render GQDs hydrophilic and biocompatible but also facilitate functionalization, enabling specific interactions with biological systems. Functionalization of GQDs with amino (&#x2013;NH<sub>2</sub>) or carboxyl (&#x2013;COOH) groups further differentiates their biological and chemical properties. Amino-functionalized GQDs (NH<sub>2</sub>-GQDs) exhibit enhanced interaction with biological systems, as the amino groups can facilitate cell penetration and targeting, making them suitable for applications in bioimaging and drug delivery. The amine groups can form amide bonds with biomolecules, enhancing the stability and biocompatibility of the complexes formed. On the other hand, Carboxylated GQDs (COOH-GQDs) have strong acidic properties and can interact with positive charges on the surface of proteins and other biomolecules. This interaction capability makes COOH-GQDs particularly useful in biosensing and molecular recognition applications, where selective binding to target molecules is crucial. GQDs&#x2019; surface chemistry and their functionalization confer them higher specificity in biological and chemical interactions. That makes them of particular interest in nanotechnology (<xref ref-type="bibr" rid="ref17">Henna and Pramod, 2020</xref>). For these reasons, recently, the interest in GQDs has widely spread toward different branches of biology and medicine, making them excellent candidates for use in bioimaging, drug delivery and in theranostic applications (<xref ref-type="bibr" rid="ref34">Perini et al., 2020</xref>).</p>
<p>Studies on the graphene-family of nanomaterials led to the development by Ponomarenko and Geim in 2008 of GQDs, that were considered more suitable for biological applications than any other quantum dots (<xref ref-type="bibr" rid="ref17">Henna and Pramod, 2020</xref>). Indeed, GQDs are carbon-based zero-dimensional fluorescent nanomaterials with a graphene lattice inside, show great solubility, have a size less than 20&#x2009;nm (maximum size of 60&#x2009;nm) and can easily penetrate through biological membranes. Additionally, GQDs suspension is very stable in a high electrolyte concentration and at low pH solutions (<xref ref-type="bibr" rid="ref17">Henna and Pramod, 2020</xref>).</p>
<p>Unlike graphene and similarly to fullerenes (C60), GQDs in suspension can generate reactive oxygen species (ROS) upon photoexcitation (<xref ref-type="bibr" rid="ref6">Christensen et al., 2011</xref>). Therefore, GQDs are potential candidates for photodynamic therapy, in which the light-excited compound kills cells by ROS generated through energy or electron transfer to molecular oxygen (<xref ref-type="bibr" rid="ref40">Robertson et al., 2009</xref>). Photodynamic therapy can also target microbial pathogens, including bacteria, which is becoming increasingly relevant considering the emerging antibiotic resistance and consequent reduction in effectiveness of conventional therapies. While most carbon-based nanomaterials, including fullerenes, carbon nanotubes and graphene display antibacterial properties (<xref ref-type="bibr" rid="ref22">Liu et al., 2011</xref>), the effects of GQDs on bacteria have not been investigated so far. It has been shown that electrochemically produced GQDs generate reactive oxygen species when photoexcited (470&#x2009;nm, 1&#x2009;W), and can kill two strains of pathogenic bacteria as methicillin-resistant <italic>Staphylococcus aureus</italic> and <italic>Escherichia coli</italic> (<xref ref-type="bibr" rid="ref39">Ristic et al., 2014</xref>). Moreover, small-sized GQDs may assist in the drug delivery process thanks to their ability to permeate vertically the lipid membrane on a nanosecond timescale, without mechanically causing damage (<xref ref-type="bibr" rid="ref49">Xue et al., 2019</xref>).</p>
<p>In this work, our interest was to investigate the role of GQDs as antimycobacterial compounds alone or in combination with anti-<italic>Mtb</italic> drugs in <italic>in vitro</italic> and in <italic>ex vivo</italic> infection models.</p>
</sec>
<sec sec-type="results" id="sec2">
<title>Results</title>
<sec id="sec3">
<title>Characterization of GQDs</title>
<p>GQDs underwent comprehensive characterization encompassing optical density, fluorescence intensity, dynamic light scattering (DLS), zeta potential, and attenuated total reflection-Fourier transform infrared spectroscopy (FTIR). The outcomes are depicted in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Both L-GQDs and COOH-GQDs exhibited an absorption shoulder at 350&#x2009;nm, whereas NH<sub>2</sub>-GQDs demonstrated a shifted absorption peak toward 400&#x2009;nm (<xref ref-type="fig" rid="fig1">Figures 1A</xref>&#x2013;<xref ref-type="fig" rid="fig1">C</xref>). Fluorescence intensity spectra were recorded by exciting GQDs from 250 to 520&#x2009;nm and measuring emission from 300 to 700&#x2009;nm with a 10&#x2009;nm step size. Data normalization was performed relative to the highest recorded emission for each GQD. L-GQDs manifested an emission peak at 380&#x2009;nm when excited at 330&#x2009;nm (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). NH<sub>2</sub>-GQDs exhibited maximum emission at 450&#x2009;nm when excited at 380&#x2009;nm (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). COOH-GQDs displayed an emission peak at 450&#x2009;nm when excited at 330&#x2009;nm (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). DLS and zeta potential analyses were conducted, indicating a consistent size distribution with a hydrodynamic radius peaked below 10&#x2009;nm for all particles (<xref ref-type="fig" rid="fig1">Figures 1G</xref>&#x2013;<xref ref-type="fig" rid="fig1">I</xref>). Zeta potential measurements revealed distinct surface net charges for the three chemically functionalized nanoparticles. L-GQDs and COOH-GQDs exhibited more negative charges, as anticipated (<xref ref-type="bibr" rid="ref32">Perini et al., 2020</xref>), compared to NH<sub>2</sub>-GQDs (<xref ref-type="fig" rid="fig1">Figures 1G</xref>&#x2013;<xref ref-type="fig" rid="fig1">I</xref>). L-GQDs possessed a surface charge of &#x2212;47.3&#x2009;&#x00B1;&#x2009;5.95&#x2009;mV, while COOH-GQDs showed a less negative charge of &#x2212;21.2&#x2009;&#x00B1;&#x2009;2.93&#x2009;mV. Due to the presence of amino groups, NH<sub>2</sub>-GQDs exhibited a zeta potential of &#x2212;3.2&#x2009;&#x00B1;&#x2009;1.72&#x2009;mV. Surface chemical functionalization of GQDs was confirmed and examined through FTIR spectroscopy. The IR spectra of L-GQDs revealed two bands in the fingerprint region typical of the C=O bond (bands 1 and 2, <xref ref-type="fig" rid="fig1">Figure 1J</xref>) (<xref ref-type="bibr" rid="ref30">Perini et al., 2023</xref>). NH<sub>2</sub>-GQDs displayed a broad band around 3,000&#x2009;cm<sup>&#x2212;1</sup>, corresponding to the N&#x2013;H stretching vibration of amine groups (<xref ref-type="fig" rid="fig1">Figure 1K</xref>, peak 1). Peaks in the fingerprint region indicated the presence of amide I and amide II, while a broader band at around 1,400&#x2009;cm<sup>&#x2212;1</sup> indicated C-N absorption (<xref ref-type="fig" rid="fig1">Figure 1K</xref>, peaks 2 and 3, respectively). The IR spectra of COOH-GQDs exhibited characteristic frequencies of the carboxylic group, a broad band between 3,500&#x2013;2,500&#x2009;cm<sup>&#x2212;1</sup> for the O-H stretch (<xref ref-type="fig" rid="fig1">Figure 1L</xref>, peak 1), and a prominent band at 1705&#x2009;cm<sup>&#x2212;1</sup> for the C=O stretch (<xref ref-type="fig" rid="fig1">Figure 1L</xref>, peak 2).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Characterization of GQDs. Optical density of L-GQDs, NH2-GQDs and COOH-GQDs, respectively <bold>(A&#x2013;C)</bold>. Fluorescence spectra of L-GQDs, NH2-GQDs and COOH-GQDs by exciting from 250 to 520&#x2009;nm and recording emission from 300 to 700&#x2009;nm. Data were normalized to the highest recorded fluorescence intensity for each GQD <bold>(D&#x2013;F)</bold>. Dynamic light scattering and zeta potential of L-GQDs, NH2-GQDs and COOH-GQDs, respectively <bold>(G&#x2013;I)</bold>. IR spectra of L-GQDs, NH2-GQDs and COOH-GQDs showing their chemical composition <bold>(J&#x2013;L)</bold>.</p>
</caption>
<graphic xlink:href="fmicb-15-1395815-g001.tif"/>
</fig>
<sec id="sec4">
<title>NH<sub>2</sub>-GQDs enhances AMK activity against <italic>Mtb</italic> but does not exert any direct antimycobacterial effect alone</title>
<p>To assess the direct antimycobacterial activity of differentially functionalized GQDs (L-GQDs, NH<sub>2</sub>-GQDs and COOH-GQDs), each nanomaterial was administered alone or in combination with INH, AMK and LZD (at the respective MIC) to <italic>Mtb</italic> H37Rv culture, and antimycobacterial activity was measured 6 and 24&#x2009;h later (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). GQDs alone were not able to reduce mycobacterial counts (<italic>p</italic>&#x2009;&#x003E;&#x2009;0.05) suggesting that the trapping effect, mainly dependent on CNMs destabilization in biological fluids, was not achieved for the smaller GQDs (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Interestingly, both INH and LZD co-administrated with GQDs did not enhance their efficacy 24&#x2009;h p.i. (<italic>p</italic>&#x2009;&#x003E;&#x2009;0.05), while a slight improvement of the AMK activity was observed (<xref ref-type="fig" rid="fig2">Figures 2C</xref>&#x2013;<xref ref-type="fig" rid="fig2">E</xref>). Hence, co-administration of AMK with NH<sub>2</sub>-GQDs significantly reduced CFUs in comparison with AMK alone or AMK in combination with L-GQDs and COOH-GQDs reaching levels comparable to INH treatment (reduction: log1.13, <italic>p</italic> value &#x003C;0.001).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>GQDs and GQDs-drugs formulations activity on <italic>Mtb</italic> H37Rv. Schematic representation depicts the experimental model used to assay Graphene Quantum Dots (GQDs) and GQDs &#x2013; anti mycobacterial drugs administration on <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>) <bold>(A)</bold>. A suspension of <italic>Mtb</italic> H37Rv at the final concentration of 10<sup>5</sup> CFUs/ml was incubated with 50&#x2009;&#x03BC;g/mL GQDs (L-GQDs, NH<sub>2</sub>-GQDs and COOH-GQDs) alone or in combination with amikacin (AMK), isoniazid (INH) and linezolid (LZD) at minimal inhibitory concentrations (MICs). Untreated <italic>Mtb</italic> culture was used as control (CTR) <bold>(B&#x2013;E)</bold>. Colonies forming units were assessed 6&#x2009;h (h) and 24&#x2009;h post incubation and represented in log10 scale.</p>
</caption>
<graphic xlink:href="fmicb-15-1395815-g002.tif"/>
</fig>
<p>GQDs typically interact with cellular membrane destabilizing the lipidic shift or altering surface net charge without modifying cell uptake (<xref ref-type="bibr" rid="ref47">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="ref50">Zhang et al., 2022</xref>). Taking into account this property, we assayed the GQDs direct activity against exponentially growing mycobacterial cultures, by incubating nanoparticles alone or co-administrated with AMK, INH and LZD up to 21&#x2009;days (<xref ref-type="bibr" rid="ref46">Vilcheze et al., 2017</xref>). CFUs were determined at 0, 7, 14 and 21&#x2009;days by plating serial dilutions of the suspensions (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>GQDs and GQDs-drugs formulations activity on exponentially growing cultures of <italic>Mtb</italic> H37Rv. Schematic representation depicts the experimental model used to assay Graphene Quantum Dots (GQDs) and GQDs anti mycobacterial drugs administration on exponentially growing <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>) <bold>(A)</bold>. A solution of <italic>Mtb</italic> H37Rv at the final concentration of 10<sup>7</sup> CFUs/ml was incubated with 50&#x2009;&#x03BC;g/mL GQDs (L-GQDs, NH<sub>2</sub>-GQDs and COOH-GQDs) alone or administrated with amikacin (AMK), isoniazid (INH) and linezolid (LZD) at minimal inhibitory concentrations (MICs). Untreated <italic>Mtb</italic> culture was used as control (CTR) <bold>(B&#x2013;E)</bold>. Colonies forming units were measured at 7, 14, and 21&#x2009;days and represented in log10 scale.</p>
</caption>
<graphic xlink:href="fmicb-15-1395815-g003.tif"/>
</fig>
<p>Interestingly, neither GQDs alone nor GQDs combined with INH and LZD exhibited a significant antimicrobial effect compared to INH and LZD treatment (<xref ref-type="fig" rid="fig3">Figures 3B</xref>,<xref ref-type="fig" rid="fig3">D</xref>,<xref ref-type="fig" rid="fig3">E</xref>). Conversely, NH<sub>2</sub>-GQDs &#x2013; AMK administration appeared the only combination to slightly reduce CFUs, maintaining at 21&#x2009;days similar levels to AMK alone (<italic>p</italic>&#x2009;&#x003E;&#x2009;0.05). While 7&#x2009;days p.i., AMK alone appeared significantly more efficient than GQDs-AMK combinations, NH<sub>2</sub>-GQDs &#x2013; AMK administration determined a major CFUs decreasing at 14&#x2009;days (reduction: log1.61, <italic>p</italic>&#x2009;&#x003C;&#x2009;0.001) (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p>
<p>Taken together these results indicate that GQDs do not exert antimycobacterial activity except for the combined use of NH<sub>2</sub>- NH<sub>2</sub>-GQDs that enhanced the antimycobacterial activity of AMK when co-administered. Furthermore, the major aminated GQDs-AMK activity, compared to material or drug alone, appears dependent on the mycobacterial count.</p>
</sec>
<sec id="sec5">
<title>NH<sub>2</sub>-GQDs &#x2013; AMK co-administration improves antimycobacterial drug activity during macrophages infection</title>
<p>Given the proven efficacy of GQDs to perturb the cell&#x2019;s lipidic membrane and increase its permeability (<xref ref-type="bibr" rid="ref34">Perini et al., 2020</xref>), we tested the GQDs-drugs activity in <italic>in vitro</italic> models of <italic>Mtb</italic> infection based on murine macrophages (J774 A.1 cell line).</p>
<p>Biocompatibility of GQDs on eukaryotic cells was measured by incubating J774 with L-GQDs, NH<sub>2</sub>-GQDs and COOH-GQDs, as previously described (<xref ref-type="bibr" rid="ref31">Perini et al., 2023</xref>). Following 24&#x2009;h of incubation, we did not observe differences between the functionalized GQDs in terms of Lactate DeHydrogenase (LDH) release, metabolic activity (MTS assay) and monolayer integrity (Cristal violet staining) (<xref ref-type="fig" rid="fig4">Figure 4</xref>). The percentage of cytotoxicity measured by the LDH release revealed a cytotoxicity of functionalized GQDS comparable to that of untreated cells (0.05, 0.05 and 0.01%, for L-GQDs, NH<sub>2</sub>-GQDs and COOH-GQDs, respectively). Furthermore, MTS assay results showed that the metabolic activity of macrophages was not affected by GQDs, suggesting that neither cellular activation nor cellular death were induced by nanomaterials. As expected, treatment with Triton X-100 significantly decreased metabolic activity as compared to control (<italic>p</italic> value &#x003C;0.01). MTS assay was also performed on hepatic immortalized cells (HepG2) and renal immortalized cells (Vero) confirming GQDs&#x2019; biocompatibility (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 1</xref>).</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Assessment of GQDs&#x2019; cytotoxicity on murine macrophages. Murine macrophages (J774) were seeded in a 96 well plate. When 90% cell monolayer was reached, cells were treated with 50&#x2009;&#x03BC;g/mL GQDs. Untreated cells and cells treated with 2% Triton X-100 were used as negative and positive controls, respectively <bold>(A)</bold>. One day post-incubation, Lactate DeHydrogenase (LDH) was measured in culture supernatant and cytotoxicity was expressed as percentage of LDH release normalized on negative and positive controls <bold>(B)</bold>. The metabolic activity was evaluated following MTS assay, and the images of cellular monolayer&#x2019;s integrity were acquired by using cytation instrument after crystal violet staining <bold>(C,D)</bold>.</p>
</caption>
<graphic xlink:href="fmicb-15-1395815-g004.tif"/>
</fig>
<p>J774 were infected with <italic>Mtb</italic> for 1&#x2009;h (MOI of 1:1), then extracellular bacteria were removed, and cells treated with GQDs for 1&#x2009;day. Finally, INH, AMK and LZD were administrated at the indicated concentrations. Cells were incubated in standard atmosphere conditions for additional 24&#x2009;h when CFUs were assessed by plating serial dilutions of each condition (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). No significant anti-mycobacterial activity was observed at 24&#x2009;h p.i. for macrophages treated with L-GQDs and COOH-GQDs alone, while treatment with NH<sub>2</sub>-GQDs resulted in a reduction of CFUs (<italic>p</italic>&#x2009;=&#x2009;0.014) when compared to untreated cells (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Additionally, NH<sub>2</sub>-GQDs and COOH-GQDs significantly enhanced AMK activity at 48&#x2009;h p.i. in comparison with untreated macrophages, by promoting a reduction of 1.12 Log CFU (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.01) and 1.07 LogCFU, respectively, with the latter difference not reaching statistically significance compared to macrophages treated with AMK alone (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Conversely, all tested GQDs did not enhance INH and LZD activities (<xref ref-type="fig" rid="fig5">Figures 5D</xref>,<xref ref-type="fig" rid="fig5">E</xref>). These results show that NH<sub>2</sub>-GQDs slightly improves macrophagic response against mycobacterial replication and that NH<sub>2</sub>-GQDs and COOH-GQDs enhance AMK antimycobacterial activity when macrophages are pre-treated with these nanomaterials.</p>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption>
<p>GQDs-drugs effects during <italic>Mtb</italic> infection on differentiated macrophages. Murine macrophages (J774) were infected with <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>) H37Rv (MOI&#x2009;=&#x2009;1:1). One hour after infection, cells were washed and treated with 50&#x2009;&#x03BC;g/mL GQDs (L-GQDs, NH<sub>2</sub>-GQDs and COOH-GQDs). The next day, the medium was removed and new fresh medium containing amikacin (AMK), isoniazid (INH) and linezolid (LZD) at minimal inhibitory concentrations (MICs) was added <bold>(A)</bold>. Colony forming units (CFUs) were evaluated 24&#x2009;h post treatment <bold>(B&#x2013;E)</bold> and represented in log10 scale.</p>
</caption>
<graphic xlink:href="fmicb-15-1395815-g005.tif"/>
</fig>
</sec>
<sec id="sec6">
<title>GQDs does not control <italic>Mtb</italic> replication in hPBMCs</title>
<p>We have recently demonstrated that GO exerts a generalized toxic effect on human PBMCs (<xref ref-type="bibr" rid="ref41">Salustri et al., 2023</xref>), hence we aimed to investigate whether GQDs have any toxicity in similar settings. We assessed cellular viability 1&#x2009;h post treatment measuring 7AAD PC5.5-A signal (7AAD PC5.5-A binds DNA with high affinity and it is efficiently excluded by viable cells resulting an optimal marker for dead cells which have damaged nuclear membranes). To corroborate FACS analysis, MTS assay was performed on hPBMCs stimulated with GQDs for 1&#x2009;h and 24&#x2009;h (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). GQDs did not show any toxicity on hPBMCs at both 1&#x2009;h and 24&#x2009;h post treatment (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Among the leukocytes, both lymphocytes (CD3 positive cells) and monocytes (CD64 positive population) were not affected by GQDs (<xref ref-type="fig" rid="fig6">Figures 6C</xref>,<xref ref-type="fig" rid="fig6">D</xref>) and the percentage of living cells was comparable to that measured in the untreated samples (20 and 8%, respectively), while less than 1&#x2013;2% appeared dead after treatment. These results suggest that no cytotoxicity was induced by GQDs on hPBMCs.</p>
<fig position="float" id="fig6">
<label>Figure 6</label>
<caption>
<p>Assessment of GQDs&#x2019; cytotoxicity on hPBMCs and on whole blood cells. Human Peripheral Blood Mononuclear Cells (hPBMCs) were isolated from healthy donors and treated with GQDs for 1 and 24&#x2009;h <bold>(A)</bold>. After incubation, MTS assay was performed to evaluate cellular metabolic activity, using untreated cells and cells treated with 2% Triton X-100 as negative and positive controls, respectively <bold>(B)</bold>. Furthermore, the peripheral whole blood was incubated with 50&#x2009;&#x03BC;g/mL GQDs (L-GQDs, NH<sub>2</sub>-GQDs and COOH-GQDs) for 1&#x2009;h at 37&#x00B0;C. Cells viability was measured through flow cytometry analysis by using 7AAD PC5.5-A staining and Side Scatter (SSC-A) gating. Viability of lymphocytes <bold>(C)</bold> and monocytes <bold>(D)</bold> was quantitatively assessed after treatment with nanomaterials.</p>
</caption>
<graphic xlink:href="fmicb-15-1395815-g006.tif"/>
</fig>
<p>To investigate whether GQDs were able to affect <italic>Mtb</italic> viability in this model of infection, hPBMCs isolated from healthy donors were infected with <italic>Mtb</italic> H37Rv, treated with GQDs 24&#x2009;h p.i., before AMK, INH and LZD administration 3&#x2009;days later (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). Bacterial survival was finally evaluated 8&#x2009;days post-infection. As shown in <xref ref-type="fig" rid="fig7">Figure 7B</xref>, GQDs alone did not affect mycobacterial replication compared to the untreated hPBMCs. Moreover, no minor effects were observed when antibiotics were administrated together on GQDs pre-treated cells (<italic>p</italic>&#x2009;&#x003E;&#x2009;0.05) (<xref ref-type="fig" rid="fig7">Figures 7C</xref>&#x2013;<xref ref-type="fig" rid="fig7">E</xref>).</p>
<fig position="float" id="fig7">
<label>Figure 7</label>
<caption>
<p>GQDs-drugs cytotoxicity effects on <italic>Mtb ex vivo</italic> hPBMCs infection model. Human peripheral blood mononuclear cells (hPBMCs), isolated from healthy donors, were infected with <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>) H37Rv (MOI of 1 respect to monocytes, corresponding to ~5% of the hPBMCs, ~ 6&#x00D7;10<sup>4</sup> cells). One day after infection, cells were treated with 50&#x2009;&#x03BC;g/mL GQDs (L-GQDs, NH<sub>2</sub>-GQDs and COOH-GQDs) <bold>(A)</bold>. Four days post infection, amikacin (AMK), isoniazid (INH) and linezolid (LZD) at minimal inhibitory concentrations (MICs) were administrated. Colony forming units (CFUs) were evaluated at 4- and 8-days post infection and represented in log10 scale <bold>(B&#x2013;E)</bold>.</p>
</caption>
<graphic xlink:href="fmicb-15-1395815-g007.tif"/>
</fig>
<p>These results corroborated the absence of GQDs toxicity on hPBMCs and highlight, at least in these formulations and using this experimental setting, no evident activity against <italic>Mtb</italic> infection. Moreover, non-functionalized L-GQDs may also have a opposite effect in controlling mycobacterial replication.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion" id="sec7">
<title>Discussion</title>
<p>The last 10&#x2009;years have seen a growing interest in the medical application of CNM and particularly of GO, mostly thanks to its biocompatibility, antimicrobial properties and, regarding <italic>Mtb</italic> infection, its ability to accumulate in the lungs (<xref ref-type="bibr" rid="ref51">Zhang et al., 2011</xref>; <xref ref-type="bibr" rid="ref28">Park et al., 2015</xref>; <xref ref-type="bibr" rid="ref25">Palmieri et al., 2017</xref>; <xref ref-type="bibr" rid="ref10">De Maio et al., 2019</xref>). We have demonstrated that GO can entrap extracellular mycobacteria (<xref ref-type="bibr" rid="ref11">De Maio et al., 2019</xref>) and, depending on its surface-exposed functional groups, enhances the anti-<italic>Mtb</italic> activity of LZD, but not of INH and AMK (<xref ref-type="bibr" rid="ref12">De Maio et al., 2020</xref>). However, GO exerts a toxic effect on immune cells reducing monocytes viability and prompting an early activation of CD4 lymphocytes (<xref ref-type="bibr" rid="ref41">Salustri et al., 2023</xref>).</p>
<p>Among CNMs, GQDs raised interest in biomedical applications and may provide effective and less toxic scaffolds against bacterial infections, including those caused by mycobacteria. GQDs are readily cleared from the body, a key feature for their biocompatibility. <italic>In vivo</italic> biodistribution experiments of GQDs revealed no accumulation in main organs of mice and fast clearance through kidney. Furthermore, multi-dosing administration of GQDs did not show any influence on mice owing to its small size, while GO appeared toxic, even caused mice death (<xref ref-type="bibr" rid="ref5">Chong et al., 2014</xref>).</p>
<p>The uptake and clearance of GQDs appear both cell type dependent and GQDs surface charge dependent. GQDs with similar sizes (~5&#x2013;8&#x2009;nm) but carrying different surface charges (cationic and anionic) show differences in their uptake and clearance in melanoma cells (<xref ref-type="bibr" rid="ref37">Ramana et al., 2021</xref>). Both GQDs exhibited comparable biocompatibility, with the cationic GQDs showing a faster and higher uptake compared to anionic GQDs. Consequently, a relatively rapid clearance was observed in cells treated with anionic GQDs compared to those treated with cationic GQDs (<xref ref-type="bibr" rid="ref37">Ramana et al., 2021</xref>). Based on these observations, we set up a series of experiments to investigate the role of differently functionalized GQDs against <italic>Mtb</italic> infection.</p>
<p>GQDs significantly improve GO aqueous stability while maintaining wide chemical adaptability and high adsorption capacity (<xref ref-type="bibr" rid="ref5">Chong et al., 2014</xref>). Our results highlight that GQDs alone do not directly affect mycobacterial viability. Nevertheless, GQDs show direct effect when co-administrated with anti-TB drugs; in particular, NH<sub>2</sub>-GQDs &#x2013; AMK and COOH-GQDs &#x2013; AMK combinations significantly reduce CFUs in comparison with AMK alone or its combination with not functionalized L-GQDs. Importantly, combining GQDs with AMK or INH does not promote precipitation of the nanomaterial (data not shown), allowing the conservation of the drug activity, different to what observed for GO (<xref ref-type="bibr" rid="ref12">De Maio et al., 2020</xref>). While aqueous solubility and stability of GO are mainly dependent on the oxygen-rich functional groups at the sheets&#x2019; edges, this problem is overcome for GQDs due their smaller size. Unfortunately, their size prevents the aggregation in biological fluids observed for GO, thus mycobacteria entrapment in nanomaterial-like nets.</p>
<p>Clearance of GQDs, and more in general of nanomaterials, is executed by macrophages which are responsible for recognizing and ingesting these particles (<xref ref-type="bibr" rid="ref14">Dobrovolskaia et al., 2017</xref>). Macrophages also represents the first line of host defense and trigger the early immune response against mycobacteria (<xref ref-type="bibr" rid="ref1">Ahmad et al., 2022</xref>). Previous experiments demonstrated that GQDs were engulfed in the murine J774 macrophage cell lines thus stimulating intracellular ROS production that interferes with macrophages proliferation (<xref ref-type="bibr" rid="ref36">Qu et al., 2013</xref>). J774 is a globally used model to assay <italic>Mtb</italic> infection that we adopted for our experiments. Contrary to what observed by Qu and colleagues, we did not observe any toxicity following GQDs treatments, confirming that surface modification ensured the function and the safety of the GQDs. Moreover, GQDs are increasingly recognized as anti-cancer drug carriers in many experiments due to their ability to facilitate the permeation of drugs into the lipid bilayer with less deformation of the cell membrane structure (<xref ref-type="bibr" rid="ref49">Xue et al., 2019</xref>; <xref ref-type="bibr" rid="ref34">Perini et al., 2020</xref>). Drug translocation, related to small later size, and the promising interaction with the biomembrane, suggested a possible role of GQDs as anti-TB adjuvant therapy that could enhance cell entry of several drugs used in TB management, known to show low permeability (<xref ref-type="bibr" rid="ref38">Rey-Jurado et al., 2013</xref>; <xref ref-type="bibr" rid="ref16">Hashemian et al., 2018</xref>).</p>
<p>Additionally, macrophages exposed to GQDs increase the presence of phosphoglycerides, sphingolipids, and oxidized lipids (<xref ref-type="bibr" rid="ref42">Shao et al., 2023</xref>). While not completely elucidated, the role of host lipids and the changes associated with Mtb infection, play a key role in the pathogenesis of TB (<xref ref-type="bibr" rid="ref13">De Maio et al., 2021</xref>). Indeed, we have recently demonstrated that phosphoglycerides such as phosphorylated phosphatidylinositol (PtdIns), cardiolipin (CL), and phosphatidic acid (PA), were recognized by a surface protein of <italic>Mtb</italic> which appears to ensure phosphate acquisition from the environment and mediate adhesion to host cell. Alternatively, sphingolipids accumulation in the eukaryotic membrane directly induces cell death (<xref ref-type="bibr" rid="ref21">Lee et al., 2023</xref>). Additionally, the synthesis of sphingolipids, but not glycosphingolipids, is required for the phagocytosis of specific pathogens such as <italic>Mtb</italic>, thereby modulating actin dynamics and the formation of the phagocytic cup during engulfment and internalization (<xref ref-type="bibr" rid="ref21">Lee et al., 2023</xref>). Hence, it will be important to investigate the consequences of GQDs on the homeostasis of lipids in infected macrophages.</p>
<p><italic>Mtb</italic> has the potential to modulate macrophage polarization, with the balance of proinflammatory and anti-inflammatory macrophages driving the outcome of single granulomatous lesions (<xref ref-type="bibr" rid="ref24">Mattila et al., 2013</xref>; <xref ref-type="bibr" rid="ref4">Cadena et al., 2017</xref>). GQDs immunoregulatory properties are insufficiently investigated, especially in human primary immune cells (<xref ref-type="bibr" rid="ref15">Habtamu et al., 2018</xref>), and certainly warrant detailed a conclusive investigation. Indeed, GQDs have been demonstrated to switch the polarization of macrophages from classically activated M1 to M2, enhancing intestinal infiltration of regulatory T cells and inhibiting Th1/Th17 polarization (<xref ref-type="bibr" rid="ref19">Lee et al., 2020</xref>). T cell mediated immune responses of the Th1 type are widely regarded as protective against TB. The Th1 cytokine, interferon gamma (IFN-&#x03B3;) is considered a key protective cytokine based on earlier studies, in both mice and humans, which showed that defects in the IFN-&#x03B3; signaling pathways provoked higher susceptibility to Mtb infection and severe disease (<xref ref-type="bibr" rid="ref15">Habtamu et al., 2018</xref>). Additionally, GQDs also reduced the numbers of interferon-&#x03B3;-expressing T helper 1 cells, as well as the expression of Th1 transcription factor T-bet and proinflammatory cytokines TNF, IL-1, and GMSF (<xref ref-type="bibr" rid="ref45">Tosic et al., 2019</xref>). While M1 polarized macrophages mediate inflammatory responses and increase the microbicidal activity, M2 polarized macrophages are related to persistent infection determining the escape of mycobacteria (<xref ref-type="bibr" rid="ref18">Huang et al., 2015</xref>). Based on these findings, we shifted our experiments on human PBMCs that allow to investigate <italic>Mtb</italic> replication containment mediated by different cell types and in particularly the combination of both monocytes/macrophages and lymphocytes. Intriguingly, human PBMCs failed to control <italic>Mtb</italic> replication when treated with GQDs similarly to GO without affecting cell viability. We can speculate that non-toxic doses of GQDs may inhibit the production of proinflammatory and T helper 1 cytokines and augment the production of anti-inflammatory and Th2 cytokines by human PBMCs lead to uncontrolled <italic>Mtb</italic> replication (<xref ref-type="bibr" rid="ref44">Tomic et al., 2017</xref>). Intriguingly, GQDs lowered the production of the target of rapamycin (mTOR), which correlated with the increase in autophagic flux in monocytes derived dendritic cells DC that could be another key point in failing <italic>Mtb</italic> replication control as we have demonstrated for other innovative anti-TB treatments (<xref ref-type="bibr" rid="ref3">Bianco et al., 2023</xref>).</p>
<p>The emerging research and development in GQDs reveal their potential application in the biomedical field. Based on our observations, aminated GQDs when administrated with AMK appeared to increase the antimycobacterial drug efficacy, reducing the number of live mycobacteria. Our results elucidate the role of GQDs against <italic>Mtb</italic> infection, underlining its promising activity in macrophages but suggesting possible side effects on hPBMCs. These findings also suggest that beneficial effects in inflammatory T-cell mediated pathologies due to GQDs may be balanced with harmful in GQD-based anti-TB treatment as well as anti-cancer therapy.</p>
</sec>
<sec sec-type="materials|methods" id="sec8">
<title>Materials and methods</title>
<sec id="sec9">
<title>Characterization of GQDs</title>
<p>L-GQDs, NH<sub>2</sub>-GQDs and COOH-GQDs in aqueous solution were purchased from ACS Material. Optical density and fluorescence intensity spectra were obtained with a Cytation 3 Cell Imaging Multi-Mode Reader (Biotek). Both optical density and fluorescence intensity were recorded on samples diluted at 100&#x2009;&#x03BC;g/mL as previously described (<xref ref-type="bibr" rid="ref27">Papi et al., 2019</xref>; <xref ref-type="bibr" rid="ref33">Perini et al., 2020</xref>, <xref ref-type="bibr" rid="ref29">2021</xref>, <xref ref-type="bibr" rid="ref35">2022</xref>). Fluorescence intensity was investigated by using excitation wavelengths from 250 to 520&#x2009;nm with a step size of 10&#x2009;nm and reading the emission from 300 to 700&#x2009;nm. Fluorescence spectra were normalized to their corresponding maximum emission. Dynamic light scattering and zeta potential analyses were conducted using the Zetasizer Nano ZS (Malvern), equipped with a 633-nm He&#x2212;Ne laser and operating at an angle of 173&#x00B0;. UV-transparent cuvettes were employed for experiments featuring a sample volume of 500&#x2009;&#x03BC;L and a concentration of 100&#x2009;&#x03BC;g/mL. Measurements were executed at a fixed position (4.65&#x2009;mm) with an automatic attenuator. Each sample underwent three measurements, and the diffusion coefficient (D) was determined through cumulants&#x2019; analysis of autocorrelation functions. The equivalent hydrodynamic radius (Z-average size) was calculated using the Stokes&#x2212;Einstein equation. Data analysis was conducted using the Malvern Zetasizer software. Chemical analysis of GQDs was conducted by using the spectrophotometer LUMOS II Bruker in ATR mode through Fourier transform infrared spectroscopy (FTIR). The specimen under examination was directly positioned on the crystal, and the resulting spectra were recorded within the wavenumber range of 4,000&#x2013;600&#x2009;cm<sup>&#x2212;1</sup>.</p>
<sec id="sec10">
<title>Bacterial manipulation</title>
<p>Each experiment was performed by using the <italic>Mycobacterium tuberculosis</italic> (<italic>Mtb</italic>) reference strain <italic>Mtb</italic> H37Rv. Bacteria were grown in 7H9 broth medium (Difco) enriched with 10% albumin dextrose catalase (ADC) (Sigma-Aldrich) and 0.05% Tween 80 (Sigma-Aldrich), at 37&#x00B0;C and 110&#x2009;rpm agitation, until an OD<sub>600</sub> between 0.5 and 0.8 was reached. Bacterial cell culture was added with 20% sterile pure glycerol (Carlo Erba Reagents, Italy) and stored at &#x2212;80&#x00B0;C. All experiments that involved <italic>Mtb</italic> manipulation were performed in Biosafety level 3 laboratory (BSL3) in the Institute of Microbiology of Fondazione Policlinico Universitario A. Gemelli (<xref ref-type="bibr" rid="ref8">De Maio et al., 2021</xref>).</p>
</sec>
<sec id="sec11">
<title><italic>In vitro</italic> antimicrobial assay</title>
<p>To assess direct activity of GQDs, a suspension of <italic>Mtb</italic> H37Rv (10^5 CFUs/ml) was incubated alone or with GQDs Blue Luminescent (L-GQDs), Aminated GQDs (NH<sub>2</sub>-GQDs), or Carboxylated GQDs (COOH-GQDs) (ACS Material) at the final concentration of 50&#x2009;&#x03BC;g/mL, or in combination with isoniazid (INH), amikacin (AMK) and linezolid (LZD) at the minimal inhibitory concentrations of 0.2&#x2009;&#x03BC;g/mL, 1&#x2009;&#x03BC;g/mL and 1&#x2009;&#x03BC;g/mL, respectively (<xref ref-type="bibr" rid="ref11">De Maio et al., 2019</xref>, <xref ref-type="bibr" rid="ref12">2020</xref>). Bacteria were incubated in 7H9 medium enriched with 10% ADC and 0.05% Tween80 at 37&#x00B0;C. Six and 24&#x2009;h post incubation colony forming units (CFUs) were determined by plating serial dilutions of the suspensions on 7H11 solid medium (Difco) supplemented with 10% Oleic Albumin Dextrose Catalase (OADC) (Sigma-Aldrich) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The antimicrobial assay with exponentially growing cultures was executed by incubating <italic>Mtb</italic> H37Rv (10^7 CFUs/ml) with non-functionalized L-GQDs and functionalized NH<sub>2</sub>-GQDs and COOH-GQDs alone or in combination with INH, AMK and LZD anti-mycobacterial drugs at the previously described conditions (<xref ref-type="bibr" rid="ref46">Vilcheze et al., 2017</xref>). CFUs were determined at 0 (infection solution), 7, 10 and 21&#x2009;days by plating serial dilutions of the suspensions on 7H11 solid medium (Difco) supplemented with 10% Oleic Albumin Dextrose Catalase (OADC) (Sigma-Aldrich) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p>
</sec>
<sec id="sec12">
<title>Evaluation of cytotoxicity on eukaryotic cells</title>
<p>To measure cell viability under GQDs treatment, murine macrophages (J774 A.1 cell line) were cultured as described and then plated at the final concentration of 1.2&#x2009;&#x00D7;&#x2009;10^6 cell/ml in a 96-well plate. J774 cells were incubated overnight at standard atmosphere conditions (37&#x00B0;C and 5% CO<sub>2</sub>), until they were incubated with L-GQDs, NH<sub>2</sub>-GQDs and COOH-GQDs at concentrations of 50&#x2009;&#x03BC;g/mL. Untreated cells were used as negative control, cells treated with 2% Triton X-100 as positive control. Triton X-100 interacts with lipid bilayers in a non-specific way, solubilizing bio-membranes and causing cell death (<xref ref-type="bibr" rid="ref20">Koley and Bard, 2010</xref>; <xref ref-type="bibr" rid="ref23">Mattei et al., 2017</xref>). Cells were incubated 24&#x2009;h until lactate dehydrogenase (LDH) were measured, and cells were stained to assess monolayer integrity.</p>
<p>Briefly, LDH was evaluated on the supernatants of treated cells opportunely centrifuged to remove GQDs in the solution. Each supernatant was diluted before incubation with the substrate. Thirty minutes later, absorbance at 490&#x2009;nm and 680&#x2009;nm was measured using an automatic microplate reader, Cytation 5 Cell Imaging Multi-Mode Reader (Biotek Instruments). The percentage of cytotoxicity given by the LDH release is calculated as: <inline-formula>
<mml:math id="M1">
<mml:mo>%</mml:mo>
<mml:mi mathvariant="italic">Cytotoxicity</mml:mi>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi mathvariant="normal">Compound</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi mathvariant="normal">L</mml:mi>
<mml:mi mathvariant="normal">D</mml:mi>
<mml:mi mathvariant="normal">H</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi mathvariant="normal">activity</mml:mi>
<mml:mo>&#x2212;</mml:mo>
<mml:mi mathvariant="normal">Spontaneus</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi mathvariant="normal">L</mml:mi>
<mml:mi mathvariant="normal">D</mml:mi>
<mml:mi mathvariant="normal">H</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi mathvariant="normal">activity</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi mathvariant="normal">Maximum</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi mathvariant="normal">L</mml:mi>
<mml:mi mathvariant="normal">D</mml:mi>
<mml:mi mathvariant="normal">H</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi mathvariant="normal">activity</mml:mi>
<mml:mo>&#x2212;</mml:mo>
<mml:mi mathvariant="normal">Spontaneus</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi mathvariant="normal">L</mml:mi>
<mml:mi mathvariant="normal">D</mml:mi>
<mml:mi mathvariant="normal">H</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi mathvariant="normal">activity</mml:mi>
</mml:mrow>
</mml:mfrac>
<mml:mspace width="0.25em"/>
<mml:mi mathvariant="normal">x</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mn>100</mml:mn>
<mml:mtext>;</mml:mtext>
</mml:math>
</inline-formula> where Spontaneus LDH activity is the value given by untreated cells and Maximum LDH activity is the value given by cells treated with Triton X-100. In the meanwhile, the cells were fixed with PFA 4% for 30&#x2009;min and stained with crystal violet for 15&#x2009;min. In another experimental setting the cells were plated and treated as previously described and the MTS Cell Proliferation Assay was performed to evaluate the cellular metabolic activity. 24&#x2009;h post-incubation with GQDs, MTS reagent was added to each well and incubate for 0.5&#x2013;4&#x2009;h at 37&#x00B0;C. Absorbance was measured at 490&#x2009;nm every half an hour (<xref ref-type="fig" rid="fig4">Figure 4A</xref>).</p>
<p>MTS assay was performed also for human immortalized hepatic (HepG2) and monkey renal (Vero) cells (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 1</xref>), and for human Peripheral Blood Mononuclear Cells (hPBMCs) (<xref ref-type="fig" rid="fig6">Figure 6A</xref>), as previously described.</p>
</sec>
<sec id="sec13">
<title>Macrophage cells culture and infection</title>
<p>Murine macrophages (J774 A.1 cell line) were cultured in Dulbecco&#x2019;s modified Eagle&#x2019;s medium (DMEM) (Euroclone) supplemented with 10% inactivated fetal bovine serum (FBS) (Euroclone, Italy), 1% L-glutamine (Euroclone) and 1% streptomycin&#x2013;penicillin (Euroclone) and were incubated at 37&#x00B0;C and 5% CO2. Adherent cells were washed with sterile warm phosphate buffered saline (PBS) (Euroclone) and removed for experiments by using 1&#x00D7; trypsin in PBS (Euroclone). Cells were counted and re-suspended in DMEM supplemented with 2% FCS and 1% L-glutamine. Finally, cells were seeded in sterile 48 well plates (Euroclone) at a concentration of 1.2&#x2009;&#x00D7;&#x2009;10^6 cells/ml and incubated overnight until infection or treatment. J774 cells were infected with <italic>Mtb</italic>, with multiplicity of infection (MOI) of 1 (1 bacterium to 1 cell), resuspended in the cell culture medium (<xref ref-type="bibr" rid="ref9">De Maio et al., 2014</xref>). One hour post infection, infected cells were washed with sterile warm PBS to remove extracellular bacteria and treated with GDQs for 1&#x2009;day. Finally, INH, AMK and LZD were administrated at the concentrations above indicated. Cells were incubated in standard atmosphere conditions for 24&#x2009;h when CFUs were assessed by harvesting cell monolayer with sterile 0.1&#x2009;mL of sterile 0.05% Triton X-100 (Sigma-Aldrich). Serial dilutions were carried out before plating on 7H11, containing 10% OADC. Plates were then incubated at 37&#x00B0;C for 15&#x2009;days (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).</p>
</sec>
<sec id="sec14">
<title>Evaluation of the cytotoxicity on peripheral whole blood cells</title>
<p>Peripheral whole blood collected by heathy volunteers and was treated with L-GQDs, NH<sub>2</sub>-GQD and COOH-GQD at the final concentrations of 50&#x2009;&#x03BC;g/mL for 1&#x2009;h at 37&#x00B0;C. Untreated whole blood was included as a control (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Cell populations were identified using a combination of 8 fluorochrome-labeled monoclonal antibodies: HLA-DR V450 (clone L243), CD45 BV500 (clone HI30), CD64 FITC (clone 10. 1), CD4 PE (clone RPA-T4), 7-Amino-Actinomycin D (7-AAD) PerCP-Cy5.5, CD3 APC-H7 (clone SK7) (BD Biosciences), CD8 PC7 (clone SFCI21Thy2D3), and CD25 APC (clone B1.49.9) (Beckman Coulter). From each suspension, an aliquot was collected and incubated with the previously described antibodies for 20&#x2009;min at room temperature. Cells were washed with PBS containing 1% bovine serum albumin (BSA), by centrifugated at 1500 RPM for 5&#x2009;min and finally resuspended in PBS. Data were acquired using the Cytoflex cytofluorimeter and analyzed using Kaluza software (Beckman Coulter) (<xref ref-type="bibr" rid="ref41">Salustri et al., 2023</xref>). Data analysis was carried out following a gating strategy composed of several and serial steps on at least 20,000 events. 7AAD PC5.5-A versus Side Scatter (SSC-A), Forward Scatter Area (FSC-A) versus SSC-A, and Forward scatter Height (FSC-H) versus FSC-A gatings were achieved to distinguish live cells from cell debris, artifacts and GQDs aggregates, by size and complexity. The following gatings were performed to distinguish cell populations: (a) CD3 APC-A750-A versus SSC-A was used to select lymphocyte population, (b) CD8 PC7-A versus CD4 PE-A was used to distinguish CD8 from CD4 lymphocyte populations; (c) a CD64 FITC-A versus SSC-A was used to evidence monocytes. Cell activation and maturation rates were analyzed using DR PB450-A versus CD25 APC-A and CD64 FITC-A versus DR PB450-A were used to evaluate lymphocytes and monocytes activation, respectively.</p>
</sec>
<sec id="sec15">
<title>Human peripheral blood mononuclear cells isolation and infection</title>
<p>Human Peripheral Blood Mononuclear Cells (hPBMCs) were isolated from buffy coats of healthy volunteers (<xref ref-type="bibr" rid="ref8">De Maio et al., 2021</xref>; <xref ref-type="bibr" rid="ref3">Bianco et al., 2023</xref>). Healthy donors were recruited among people who had recently tested negative for QFT negative, not vaccinated with BCG, male, Caucasian, and aged between 30 and 35&#x2009;years. Written informed consent was obtained from each subject involved in the study donor (ID:3715/2021). The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of Policlinico A. Gemelli for studies involving humans. Briefly, blood was diluted with sterile PBS (1:1) and gently poured into a tube containing Ficoll Human Lympholyte<sup>&#x00AE;</sup> (CEDARLANE, Ontario, Canada). Following a centrifugation at 1500 RPM for 30&#x2009;min at room temperature (23&#x00B0;C) without brake. Lymphocytes and monocytes were collected and washed with PBS. Finally, cells were resuspended in Roswell Park Memorial Institute (RPMI) 1,640 culture medium (Euroclone) enriched with 10% fetal bovine serum (Corning), 1% Glutamine (Euroclone), 1% Sodium Pyruvate (Euroclone) and plated in 48 well plate (NEST) at a final concentration of 1.2&#x2009;&#x00D7;&#x2009;10^6 cells/ml (<xref ref-type="bibr" rid="ref8">De Maio et al., 2021</xref>). hPBMCs were infected with a Multiplicity of Infection (MOI) of 1 respect to monocytes (corresponding to ~5% of the hPBMCs, ~ 6&#x00D7;10^4 cells/ml). 24&#x2009;h post infection hPBMCs were treated with L-GQDs, NH<sub>2</sub>-GQDs and COOH-GQDs. The next day, drugs were administrated at the previously indicated MIC concentration. Bacterial survival was evaluated at 4 and 8&#x2009;days post infection by CFUs counting (<xref ref-type="fig" rid="fig7">Figure 7A</xref>).</p>
</sec>
</sec>
<sec id="sec16">
<title>Statistical analysis</title>
<p>Data were collected and organized using Microsoft Excel software version 16.69.1 and were analyzed by using GraphPad Prism software version 9.0.0 (GraphPad software) and R v4.0.2. All experiments were performed in scientific duplicates and technical triplicates. All data were expressed as mean plus SD and analyzed by two-way ANOVA followed by the appropriate correction.</p>
</sec>
</sec>
<sec sec-type="data-availability" id="sec17">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref rid="SM1" ref-type="supplementary-material">Supplementary material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="sec18">
<title>Ethics statement</title>
<p>The studies involving humans were approved by Institutional Review Board (or Ethics Committee) of Policlinico A. Gemelli for studies involving humans. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p>
</sec>
<sec sec-type="author-contributions" id="sec19">
<title>Author contributions</title>
<p>GS: Writing &#x2013; review &#x0026; editing. GP: Writing &#x2013; review &#x0026; editing. AS: Writing &#x2013; review &#x0026; editing. IP: Writing &#x2013; review &#x0026; editing. RR: Writing &#x2013; review &#x0026; editing. VP: Writing &#x2013; review &#x0026; editing. CI: Writing &#x2013; review &#x0026; editing. SB: Writing &#x2013; review &#x0026; editing. MiS: Writing &#x2013; review &#x0026; editing. MaS: Writing &#x2013; review &#x0026; editing. MSp: Writing &#x2013; review &#x0026; editing. MP: Formal analysis, Resources, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. GD: Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. FM: Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec20">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research was supported by EU funding within the MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT) and by Linea D1 awarded to GD.</p>
</sec>
<ack>
<p>We would like to acknowledge the contribution of 3D Bioprinting Research Core Facility G-STeP and Microscopy Core Facility GSTeP of the Fondazione Policlinico Universitario &#x201C;A. Gemelli&#x201D; IRCCS for sample processing.</p>
</ack>
<sec sec-type="COI-statement" id="sec21">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec22">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fmicb.2024.1395815/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fmicb.2024.1395815/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Image_1.jpg" id="SM1" mimetype="image/jpeg" xmlns:xlink="http://www.w3.org/1999/xlink">
<label>SUPPLEMENTARY FIGURE S1</label>
<caption>
<p>Assessment of GQDs&#x2019; cytotoxicity on hepatic and renal immortalized cells. Hepatic immortalized cells (HepG2) and renal immortalized cells (Vero) were seeded in a 96 well plate. When 90% cell monolayer was reached, cells were treated with 50&#x2009;&#x03BC;g/ml GQDs. Untreated cells and cells treated with 2% Triton X-100 were used as negative and positive controls, respectively. The next day, MTS assay was performed to evaluate cellular metabolic activity both for hepatic cells <bold>(A)</bold> and for renal cells <bold>(B)</bold>.</p>
</caption>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname> <given-names>F.</given-names></name> <name><surname>Rani</surname> <given-names>A.</given-names></name> <name><surname>Alam</surname> <given-names>A.</given-names></name> <name><surname>Zarin</surname> <given-names>S.</given-names></name> <name><surname>Pandey</surname> <given-names>S.</given-names></name> <name><surname>Singh</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Macrophage: a cell with many faces and functions in tuberculosis</article-title>. <source>Front. Immunol.</source> <volume>13</volume>:<fpage>747799</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.747799</pub-id>, PMID: <pub-id pub-id-type="pmid">35603185</pub-id></citation>
</ref>
<ref id="ref2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Battah</surname> <given-names>B.</given-names></name> <name><surname>Chemi</surname> <given-names>G.</given-names></name> <name><surname>Butini</surname> <given-names>S.</given-names></name> <name><surname>Campiani</surname> <given-names>G.</given-names></name> <name><surname>Brogi</surname> <given-names>S.</given-names></name> <name><surname>Delogu</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>A repurposing approach for uncovering the anti-tubercular activity of FDA-approved drugs with potential multi-targeting profiles</article-title>. <source>Molecules</source> <volume>24</volume>:<fpage>4373</fpage>. doi: <pub-id pub-id-type="doi">10.3390/molecules24234373</pub-id>, PMID: <pub-id pub-id-type="pmid">31795400</pub-id></citation>
</ref>
<ref id="ref3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bianco</surname> <given-names>D. M.</given-names></name> <name><surname>De Maio</surname> <given-names>F.</given-names></name> <name><surname>Santarelli</surname> <given-names>G.</given-names></name> <name><surname>Palucci</surname> <given-names>I.</given-names></name> <name><surname>Salustri</surname> <given-names>A.</given-names></name> <name><surname>Bianchetti</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Evaluation of everolimus activity against <italic>Mycobacterium tuberculosis</italic> using in vitro models of infection</article-title>. <source>Antibiotics</source> <volume>12</volume>:<fpage>171</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics12010171</pub-id></citation>
</ref>
<ref id="ref4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cadena</surname> <given-names>A. M.</given-names></name> <name><surname>Fortune</surname> <given-names>S. M.</given-names></name> <name><surname>Flynn</surname> <given-names>J. L.</given-names></name></person-group> (<year>2017</year>). <article-title>Heterogeneity in tuberculosis</article-title>. <source>Nat. Rev. Immunol.</source> <volume>17</volume>, <fpage>691</fpage>&#x2013;<lpage>702</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri.2017.69</pub-id>, PMID: <pub-id pub-id-type="pmid">28736436</pub-id></citation>
</ref>
<ref id="ref5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname> <given-names>Y.</given-names></name> <name><surname>Ma</surname> <given-names>Y.</given-names></name> <name><surname>Shen</surname> <given-names>H.</given-names></name> <name><surname>Tu</surname> <given-names>X.</given-names></name> <name><surname>Zhou</surname> <given-names>X.</given-names></name> <name><surname>Xu</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>The in vitro and in vivo toxicity of graphene quantum dots</article-title>. <source>Biomaterials</source> <volume>35</volume>, <fpage>5041</fpage>&#x2013;<lpage>5048</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.03.021</pub-id></citation>
</ref>
<ref id="ref6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname> <given-names>I. L. S.</given-names></name> <name><surname>Sun</surname> <given-names>Y. P.</given-names></name> <name><surname>Juzenas</surname> <given-names>P.</given-names></name></person-group> (<year>2011</year>). <article-title>Carbon dots as antioxidants and prooxidants</article-title>. <source>J. Biomed. Nanotechnol.</source> <volume>7</volume>, <fpage>667</fpage>&#x2013;<lpage>676</lpage>. doi: <pub-id pub-id-type="doi">10.1166/jbn.2011.1334</pub-id></citation>
</ref>
<ref id="ref7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Maio</surname> <given-names>F.</given-names></name> <name><surname>Bianco</surname> <given-names>D. M.</given-names></name> <name><surname>Delogu</surname> <given-names>G.</given-names></name></person-group> (<year>2022</year>). <article-title>The dark side of the COVID-19 treatments on <italic>Mycobacterium tuberculosis</italic> infection</article-title>. <source>Mediterr J. Hematol. Infect. Dis.</source> <volume>14</volume>:<fpage>e2022021</fpage>. doi: <pub-id pub-id-type="doi">10.4084/MJHID.2022.021</pub-id>, PMID: <pub-id pub-id-type="pmid">35444762</pub-id></citation>
</ref>
<ref id="ref8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Maio</surname> <given-names>F.</given-names></name> <name><surname>Cingolani</surname> <given-names>A.</given-names></name> <name><surname>Bianco</surname> <given-names>D. M.</given-names></name> <name><surname>Salustri</surname> <given-names>A.</given-names></name> <name><surname>Palucci</surname> <given-names>I.</given-names></name> <name><surname>Sanguinetti</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>First description of the katG gene deletion in a <italic>Mycobacterium tuberculosis</italic> clinical isolate and its impact on the mycobacterial fitness</article-title>. <source>Int. J. Med. Microbiol.</source> <volume>311</volume>:<fpage>151506</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijmm.2021.151506</pub-id>, PMID: <pub-id pub-id-type="pmid">33906074</pub-id></citation>
</ref>
<ref id="ref9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Maio</surname> <given-names>F.</given-names></name> <name><surname>Maulucci</surname> <given-names>G.</given-names></name> <name><surname>Minerva</surname> <given-names>M.</given-names></name> <name><surname>Anoosheh</surname> <given-names>S.</given-names></name> <name><surname>Palucci</surname> <given-names>I.</given-names></name> <name><surname>Iantomasi</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Impact of protein domains on PE_PGRS30 polar localization in mycobacteria</article-title>. <source>PLoS One</source> <volume>9</volume>:<fpage>e112482</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0112482</pub-id>, PMID: <pub-id pub-id-type="pmid">25390359</pub-id></citation>
</ref>
<ref id="ref10">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Maio</surname> <given-names>F.</given-names></name> <name><surname>Palmieri</surname> <given-names>V.</given-names></name> <name><surname>De Spirito</surname> <given-names>M.</given-names></name> <name><surname>Delogu</surname> <given-names>G.</given-names></name> <name><surname>Papi</surname> <given-names>M.</given-names></name></person-group> (<year>2019</year>). <article-title>Carbon nanomaterials: a new way against tuberculosis</article-title>. <source>Expert Rev. Med. Devices</source> <volume>16</volume>, <fpage>863</fpage>&#x2013;<lpage>875</lpage>. doi: <pub-id pub-id-type="doi">10.1080/17434440.2019.1671820</pub-id>, PMID: <pub-id pub-id-type="pmid">31550943</pub-id></citation>
</ref>
<ref id="ref11">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Maio</surname> <given-names>F.</given-names></name> <name><surname>Palmieri</surname> <given-names>V.</given-names></name> <name><surname>Salustri</surname> <given-names>A.</given-names></name> <name><surname>Perini</surname> <given-names>G.</given-names></name> <name><surname>Sanguinetti</surname> <given-names>M.</given-names></name> <name><surname>De Spirito</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Graphene oxide prevents mycobacteria entry into macrophages through extracellular entrapment</article-title>. <source>Nanoscale Adv.</source> <volume>1</volume>, <fpage>1421</fpage>&#x2013;<lpage>1431</lpage>. doi: <pub-id pub-id-type="doi">10.1039/C8NA00413G</pub-id>, PMID: <pub-id pub-id-type="pmid">36132595</pub-id></citation>
</ref>
<ref id="ref12">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Maio</surname> <given-names>F.</given-names></name> <name><surname>Palmieri</surname> <given-names>V.</given-names></name> <name><surname>Santarelli</surname> <given-names>G.</given-names></name> <name><surname>Perini</surname> <given-names>G.</given-names></name> <name><surname>Salustri</surname> <given-names>A.</given-names></name> <name><surname>Palucci</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Graphene oxide-linezolid combination as potential new anti-tuberculosis treatment</article-title>. <source>Nanomaterials</source> <volume>10</volume>:<fpage>1431</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nano10081431</pub-id></citation>
</ref>
<ref id="ref13">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Maio</surname> <given-names>F.</given-names></name> <name><surname>Salustri</surname> <given-names>A.</given-names></name> <name><surname>Battah</surname> <given-names>B.</given-names></name> <name><surname>Palucci</surname> <given-names>I.</given-names></name> <name><surname>Marchionni</surname> <given-names>F.</given-names></name> <name><surname>Bellesi</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>PE_PGRS3 ensures provision of the vital phospholipids cardiolipin and phosphatidylinositols by promoting the interaction between <italic>M. tuberculosis</italic> and host cells</article-title>. <source>Virulence</source> <volume>12</volume>, <fpage>868</fpage>&#x2013;<lpage>884</lpage>. doi: <pub-id pub-id-type="doi">10.1080/21505594.2021.1897247</pub-id>, PMID: <pub-id pub-id-type="pmid">33757409</pub-id></citation>
</ref>
<ref id="ref14">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dobrovolskaia</surname> <given-names>M. A.</given-names></name> <name><surname>Shurin</surname> <given-names>M. R.</given-names></name> <name><surname>Kagan</surname> <given-names>V. E.</given-names></name> <name><surname>Shvedova</surname> <given-names>A. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Ins and outs in environmental and occupational safety studies of asthma and engineered nanomaterials</article-title>. <source>ACS Nano</source> <volume>11</volume>, <fpage>7565</fpage>&#x2013;<lpage>7571</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acsnano.7b04916</pub-id>, PMID: <pub-id pub-id-type="pmid">28737932</pub-id></citation>
</ref>
<ref id="ref15">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Habtamu</surname> <given-names>M.</given-names></name> <name><surname>Abebe</surname> <given-names>M.</given-names></name> <name><surname>Aseffa</surname> <given-names>A.</given-names></name> <name><surname>Dyrhol-Riise</surname> <given-names>A. M.</given-names></name> <name><surname>Spurkland</surname> <given-names>A.</given-names></name> <name><surname>Abrahamsen</surname> <given-names>G.</given-names></name></person-group> (<year>2018</year>). <article-title>In vitro analysis of antigen induced T cell-monocyte conjugates by imaging flow cytometry</article-title>. <source>J. Immunol. Methods</source> <volume>460</volume>, <fpage>93</fpage>&#x2013;<lpage>100</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jim.2018.06.014</pub-id>, PMID: <pub-id pub-id-type="pmid">29981305</pub-id></citation>
</ref>
<ref id="ref16">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hashemian</surname> <given-names>S. M. R.</given-names></name> <name><surname>Farhadi</surname> <given-names>T.</given-names></name> <name><surname>Ganjparvar</surname> <given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Linezolid: a review of its properties, function, and use in critical care</article-title>. <source>Drug Des. Devel. Ther.</source> <volume>12</volume>, <fpage>1759</fpage>&#x2013;<lpage>1767</lpage>. doi: <pub-id pub-id-type="doi">10.2147/DDDT.S164515</pub-id>, PMID: <pub-id pub-id-type="pmid">29950810</pub-id></citation>
</ref>
<ref id="ref17">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henna</surname> <given-names>T. K.</given-names></name> <name><surname>Pramod</surname> <given-names>K.</given-names></name></person-group> (<year>2020</year>). <article-title>Graphene quantum dots redefine nanobiomedicine</article-title>. <source>Mater. Sci. Eng. C Mater. Biol. Appl.</source> <volume>110</volume>:<fpage>110651</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.msec.2020.110651</pub-id>, PMID: <pub-id pub-id-type="pmid">32204078</pub-id></citation>
</ref>
<ref id="ref18">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>Z.</given-names></name> <name><surname>Luo</surname> <given-names>Q.</given-names></name> <name><surname>Guo</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>J.</given-names></name> <name><surname>Xiong</surname> <given-names>G.</given-names></name> <name><surname>Peng</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title><italic>Mycobacterium tuberculosis</italic>-induced polarization of human macrophage orchestrates the formation and development of tuberculous granulomas in vitro</article-title>. <source>PLoS One</source> <volume>10</volume>:<fpage>e0129744</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0129744</pub-id>, PMID: <pub-id pub-id-type="pmid">26091535</pub-id></citation>
</ref>
<ref id="ref19">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>B. C.</given-names></name> <name><surname>Lee</surname> <given-names>J. Y.</given-names></name> <name><surname>Kim</surname> <given-names>J.</given-names></name> <name><surname>Yoo</surname> <given-names>J. M.</given-names></name> <name><surname>Kang</surname> <given-names>I.</given-names></name> <name><surname>Kim</surname> <given-names>J. J.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Graphene quantum dots as anti-inflammatory therapy for colitis</article-title>. <source>Sci. Adv.</source> <volume>6</volume>:<fpage>6</fpage>. doi: <pub-id pub-id-type="doi">10.1126/sciadv.aaz2630</pub-id></citation>
</ref>
<ref id="ref20">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koley</surname> <given-names>D.</given-names></name> <name><surname>Bard</surname> <given-names>A. J.</given-names></name></person-group> (<year>2010</year>). <article-title>Triton X-100 concentration effects on membrane permeability of a single HeLa cell by scanning electrochemical microscopy (SECM)</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>107</volume>, <fpage>16783</fpage>&#x2013;<lpage>16787</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1011614107</pub-id>, PMID: <pub-id pub-id-type="pmid">20837548</pub-id></citation>
</ref>
<ref id="ref21">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>M.</given-names></name> <name><surname>Lee</surname> <given-names>S. Y.</given-names></name> <name><surname>Bae</surname> <given-names>Y. S.</given-names></name></person-group> (<year>2023</year>). <article-title>Functional roles of sphingolipids in immunity and their implication in disease</article-title>. <source>Exp. Mol. Med.</source> <volume>55</volume>, <fpage>1110</fpage>&#x2013;<lpage>1130</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s12276-023-01018-9</pub-id>, PMID: <pub-id pub-id-type="pmid">37258585</pub-id></citation>
</ref>
<ref id="ref22">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>S.</given-names></name> <name><surname>Zeng</surname> <given-names>T. H.</given-names></name> <name><surname>Hofmann</surname> <given-names>M.</given-names></name> <name><surname>Burcombe</surname> <given-names>E.</given-names></name> <name><surname>Wei</surname> <given-names>J.</given-names></name> <name><surname>Jiang</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Antibacterial activity of graphite, graphite oxide, graphene oxide, and reduced graphene oxide: membrane and oxidative stress</article-title>. <source>ACS Nano</source> <volume>5</volume>, <fpage>6971</fpage>&#x2013;<lpage>6980</lpage>. doi: <pub-id pub-id-type="doi">10.1021/nn202451x</pub-id>, PMID: <pub-id pub-id-type="pmid">21851105</pub-id></citation>
</ref>
<ref id="ref23">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattei</surname> <given-names>B.</given-names></name> <name><surname>Lira</surname> <given-names>R. B.</given-names></name> <name><surname>Perez</surname> <given-names>K. R.</given-names></name> <name><surname>Riske</surname> <given-names>K. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Membrane permeabilization induced by Triton X-100: the role of membrane phase state and edge tension</article-title>. <source>Chem. Phys. Lipids</source> <volume>202</volume>, <fpage>28</fpage>&#x2013;<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.chemphyslip.2016.11.009</pub-id>, PMID: <pub-id pub-id-type="pmid">27913102</pub-id></citation>
</ref>
<ref id="ref24">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattila</surname> <given-names>J. T.</given-names></name> <name><surname>Ojo</surname> <given-names>O. O.</given-names></name> <name><surname>Kepka-Lenhart</surname> <given-names>D.</given-names></name> <name><surname>Marino</surname> <given-names>S.</given-names></name> <name><surname>Kim</surname> <given-names>J. H.</given-names></name> <name><surname>Eum</surname> <given-names>S. Y.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms</article-title>. <source>J. Immunol.</source> <volume>191</volume>, <fpage>773</fpage>&#x2013;<lpage>784</lpage>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1300113</pub-id>, PMID: <pub-id pub-id-type="pmid">23749634</pub-id></citation>
</ref>
<ref id="ref25">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmieri</surname> <given-names>V.</given-names></name> <name><surname>Bugli</surname> <given-names>F.</given-names></name> <name><surname>Lauriola</surname> <given-names>M. C.</given-names></name> <name><surname>Cacaci</surname> <given-names>M.</given-names></name> <name><surname>Torelli</surname> <given-names>R.</given-names></name> <name><surname>Ciasca</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Bacteria meet graphene: modulation of graphene oxide nanosheet interaction with human pathogens for effective antimicrobial therapy</article-title>. <source>ACS Biomater Sci. Eng.</source> <volume>3</volume>, <fpage>619</fpage>&#x2013;<lpage>627</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acsbiomaterials.6b00812</pub-id>, PMID: <pub-id pub-id-type="pmid">33429629</pub-id></citation>
</ref>
<ref id="ref26">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palucci</surname> <given-names>I.</given-names></name> <name><surname>Delogu</surname> <given-names>G.</given-names></name></person-group> (<year>2018</year>). <article-title>Host directed therapies for tuberculosis: futures strategies for an ancient disease</article-title>. <source>Chemotherapy</source> <volume>63</volume>, <fpage>172</fpage>&#x2013;<lpage>180</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000490478</pub-id>, PMID: <pub-id pub-id-type="pmid">30032143</pub-id></citation>
</ref>
<ref id="ref27">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Papi</surname> <given-names>M.</given-names></name> <name><surname>Palmieri</surname> <given-names>V.</given-names></name> <name><surname>Digiacomo</surname> <given-names>L.</given-names></name> <name><surname>Giulimondi</surname> <given-names>F.</given-names></name> <name><surname>Palchetti</surname> <given-names>S.</given-names></name> <name><surname>Ciasca</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Converting the personalized biomolecular corona of graphene oxide nanoflakes into a high-throughput diagnostic test for early cancer detection</article-title>. <source>Nanoscale</source> <volume>11</volume>, <fpage>15339</fpage>&#x2013;<lpage>15346</lpage>. doi: <pub-id pub-id-type="doi">10.1039/C9NR01413F</pub-id>, PMID: <pub-id pub-id-type="pmid">31386742</pub-id></citation>
</ref>
<ref id="ref28">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>E. J.</given-names></name> <name><surname>Lee</surname> <given-names>G. H.</given-names></name> <name><surname>Han</surname> <given-names>B. S.</given-names></name> <name><surname>Lee</surname> <given-names>B. S.</given-names></name> <name><surname>Lee</surname> <given-names>S.</given-names></name> <name><surname>Cho</surname> <given-names>M. H.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Toxic response of graphene nanoplatelets in vivo and in vitro</article-title>. <source>Arch. Toxicol.</source> <volume>89</volume>, <fpage>1557</fpage>&#x2013;<lpage>1568</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00204-014-1303-x</pub-id>, PMID: <pub-id pub-id-type="pmid">24980260</pub-id></citation>
</ref>
<ref id="ref29">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perini</surname> <given-names>G. P. V.</given-names></name> <name><surname>Ciasca</surname> <given-names>G.</given-names></name> <name><surname>Primiano</surname> <given-names>A.</given-names></name> <name><surname>Gervasoni</surname> <given-names>J.</given-names></name> <name><surname>De Spirito</surname> <given-names>M.</given-names></name> <name><surname>Papi</surname> <given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Functionalized graphene quantum dots modulate malignancy of glioblastoma multiforme by downregulating neurospheres formation</article-title>. <source>J. Carbon Res.</source> <volume>7</volume>:<fpage>4</fpage>. doi: <pub-id pub-id-type="doi">10.3390/c7010004</pub-id></citation>
</ref>
<ref id="ref30">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perini</surname> <given-names>G. P. V.</given-names></name> <name><surname>D'Ascenzo</surname> <given-names>M.</given-names></name> <name><surname>Colussi</surname> <given-names>C.</given-names></name> <name><surname>Grassi</surname> <given-names>C.</given-names></name> <name><surname>Friggeri</surname> <given-names>G.</given-names></name> <name><surname>Augello</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Near-infrared controlled release of mesenchymal stem cells secretome from bioprinted graphene-based microbeads for nerve regeneration</article-title>. <source>Int. J. Bioprinting.</source> <volume>10</volume>:<fpage>1045</fpage>. doi: <pub-id pub-id-type="doi">10.36922/ijb.1045</pub-id></citation>
</ref>
<ref id="ref31">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perini</surname> <given-names>G. P. V.</given-names></name> <name><surname>Friggeri</surname> <given-names>G.</given-names></name> <name><surname>Augello</surname> <given-names>A.</given-names></name> <name><surname>De Spirito</surname> <given-names>M.</given-names></name> <name><surname>Papi</surname> <given-names>M.</given-names></name></person-group> (<year>2023</year>). <article-title>Carboxylated graphene quantum dots-mediated photothermal therapy enhances drug-membrane permeability, ROS production, and the immune system recruitment on 3D glioblastoma models. Cancer</article-title>. <source>Nanotechnology</source> <volume>14</volume>:<fpage>14</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12645-023-00168-9</pub-id></citation>
</ref>
<ref id="ref32">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perini</surname> <given-names>G.</given-names></name> <name><surname>Palmieri</surname> <given-names>V.</given-names></name> <name><surname>Ciasca</surname> <given-names>G.</given-names></name> <name><surname>D'Ascenzo</surname> <given-names>M.</given-names></name> <name><surname>Gervasoni</surname> <given-names>J.</given-names></name> <name><surname>Primiano</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Graphene quantum Dots' surface chemistry modulates the sensitivity of glioblastoma cells to chemotherapeutics</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>:<fpage>6301</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21176301</pub-id>, PMID: <pub-id pub-id-type="pmid">32878114</pub-id></citation>
</ref>
<ref id="ref33">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perini</surname> <given-names>G.</given-names></name> <name><surname>Palmieri</surname> <given-names>V.</given-names></name> <name><surname>Ciasca</surname> <given-names>G.</given-names></name> <name><surname>D'Ascenzo</surname> <given-names>M.</given-names></name> <name><surname>Primiano</surname> <given-names>A.</given-names></name> <name><surname>Gervasoni</surname> <given-names>J.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Enhanced chemotherapy for glioblastoma multiforme mediated by functionalized graphene quantum dots</article-title>. <source>Materials</source> <volume>13</volume>:<fpage>4139</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ma13184139</pub-id>, PMID: <pub-id pub-id-type="pmid">32957607</pub-id></citation>
</ref>
<ref id="ref34">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perini</surname> <given-names>G.</given-names></name> <name><surname>Palmieri</surname> <given-names>V.</given-names></name> <name><surname>Ciasca</surname> <given-names>G.</given-names></name> <name><surname>De Spirito</surname> <given-names>M.</given-names></name> <name><surname>Papi</surname> <given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Unravelling the potential of graphene quantum dots in biomedicine and neuroscience</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>:<fpage>3712</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21103712</pub-id>, PMID: <pub-id pub-id-type="pmid">32466154</pub-id></citation>
</ref>
<ref id="ref35">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perini</surname> <given-names>G.</given-names></name> <name><surname>Rosa</surname> <given-names>E.</given-names></name> <name><surname>Friggeri</surname> <given-names>G.</given-names></name> <name><surname>Di Pietro</surname> <given-names>L.</given-names></name> <name><surname>Barba</surname> <given-names>M.</given-names></name> <name><surname>Parolini</surname> <given-names>O.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>INSIDIA 2.0 high-throughput analysis of 3D cancer models: multiparametric quantification of graphene quantum dots photothermal therapy for glioblastoma and pancreatic cancer</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>:<fpage>3217</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms23063217</pub-id>, PMID: <pub-id pub-id-type="pmid">35328638</pub-id></citation>
</ref>
<ref id="ref36">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname> <given-names>G.</given-names></name> <name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Wang</surname> <given-names>Z.</given-names></name> <name><surname>Liu</surname> <given-names>S.</given-names></name> <name><surname>Jiang</surname> <given-names>G.</given-names></name></person-group> (<year>2013</year>). <article-title>Cytotoxicity of quantum dots and graphene oxide to erythroid cells and macrophages</article-title>. <source>Nanoscale Res. Lett.</source> <volume>8</volume>:<fpage>198</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1556-276X-8-198</pub-id>, PMID: <pub-id pub-id-type="pmid">23631472</pub-id></citation>
</ref>
<ref id="ref37">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramana</surname> <given-names>L. N.</given-names></name> <name><surname>Dinh</surname> <given-names>L. N. M.</given-names></name> <name><surname>Agarwal</surname> <given-names>V.</given-names></name></person-group> (<year>2021</year>). <article-title>Influence of surface charge of graphene quantum dots on their uptake and clearance in melanoma cells</article-title>. <source>Nanoscale Adv.</source> <volume>3</volume>, <fpage>3513</fpage>&#x2013;<lpage>3521</lpage>. doi: <pub-id pub-id-type="doi">10.1039/D0NA00935K</pub-id>, PMID: <pub-id pub-id-type="pmid">36133718</pub-id></citation>
</ref>
<ref id="ref38">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rey-Jurado</surname> <given-names>E.</given-names></name> <name><surname>Tudo</surname> <given-names>G.</given-names></name> <name><surname>Soy</surname> <given-names>D.</given-names></name> <name><surname>Gonzalez-Martin</surname> <given-names>J.</given-names></name></person-group> (<year>2013</year>). <article-title>Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against <italic>Mycobacterium tuberculosis</italic> isolates in a human macrophage model</article-title>. <source>Int. J. Antimicrob. Agents</source> <volume>42</volume>, <fpage>524</fpage>&#x2013;<lpage>530</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2013.07.014</pub-id>, PMID: <pub-id pub-id-type="pmid">24080479</pub-id></citation>
</ref>
<ref id="ref39">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ristic</surname> <given-names>B. Z.</given-names></name> <name><surname>Milenkovic</surname> <given-names>M. M.</given-names></name> <name><surname>Dakic</surname> <given-names>I. R.</given-names></name> <name><surname>Todorovic-Markovic</surname> <given-names>B. M.</given-names></name> <name><surname>Milosavljevic</surname> <given-names>M. S.</given-names></name> <name><surname>Budimir</surname> <given-names>M. D.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Photodynamic antibacterial effect of graphene quantum dots</article-title>. <source>Biomaterials</source> <volume>35</volume>, <fpage>4428</fpage>&#x2013;<lpage>4435</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.02.014</pub-id>, PMID: <pub-id pub-id-type="pmid">24612819</pub-id></citation>
</ref>
<ref id="ref40">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname> <given-names>C. A.</given-names></name> <name><surname>Evans</surname> <given-names>D. H.</given-names></name> <name><surname>Abrahamse</surname> <given-names>H.</given-names></name></person-group> (<year>2009</year>). <article-title>Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT</article-title>. <source>J. Photochem. Photobiol. B</source> <volume>96</volume>, <fpage>1</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jphotobiol.2009.04.001</pub-id>, PMID: <pub-id pub-id-type="pmid">19406659</pub-id></citation>
</ref>
<ref id="ref41">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salustri</surname> <given-names>A.</given-names></name> <name><surname>De Maio</surname> <given-names>F.</given-names></name> <name><surname>Palmieri</surname> <given-names>V.</given-names></name> <name><surname>Santarelli</surname> <given-names>G.</given-names></name> <name><surname>Palucci</surname> <given-names>I.</given-names></name> <name><surname>Mercedes Bianco</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Evaluation of the toxic activity of the graphene oxide in the ex vivo model of human PBMC infection with <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Microorganisms</source> <volume>11</volume>:<fpage>554</fpage>. doi: <pub-id pub-id-type="doi">10.3390/microorganisms11030554</pub-id>, PMID: <pub-id pub-id-type="pmid">36985128</pub-id></citation>
</ref>
<ref id="ref42">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Wang</surname> <given-names>L.</given-names></name> <name><surname>Huang</surname> <given-names>Y.</given-names></name> <name><surname>Wei</surname> <given-names>Q.</given-names></name> <name><surname>Sun</surname> <given-names>W.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Graphene quantum dots disturbed the energy homeostasis by influencing lipid metabolism of macrophages</article-title>. <source>Toxicology</source> <volume>484</volume>:<fpage>153389</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tox.2022.153389</pub-id>, PMID: <pub-id pub-id-type="pmid">36481571</pub-id></citation>
</ref>
<ref id="ref43">
<citation citation-type="other"><person-group person-group-type="author">
<name><surname>Timothy</surname> <given-names>MSR</given-names></name>
</person-group>. (<year>2022</year>). Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults without HIV infection. Available at: <ext-link xlink:href="https://www.uptodate.com/contents/treatment-of-drug-susceptible-pulmonary-tuberculosis-in-nonpregnant-adults-without-hiv-infection?source=mostViewed_widget#H42" ext-link-type="uri">https://www.uptodate.com/contents/treatment-of-drug-susceptible-pulmonary-tuberculosis-in-nonpregnant-adults-without-hiv-infection?source=mostViewed_widget#H42</ext-link>.</citation>
</ref>
<ref id="ref44">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomic</surname> <given-names>S.</given-names></name> <name><surname>Janjetovic</surname> <given-names>K.</given-names></name> <name><surname>Mihajlovic</surname> <given-names>D.</given-names></name> <name><surname>Milenkovic</surname> <given-names>M.</given-names></name> <name><surname>Kravic-Stevovic</surname> <given-names>T.</given-names></name> <name><surname>Markovic</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Graphene quantum dots suppress proinflammatory T cell responses via autophagy-dependent induction of tolerogenic dendritic cells</article-title>. <source>Biomaterials</source> <volume>146</volume>, <fpage>13</fpage>&#x2013;<lpage>28</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.08.040</pub-id>, PMID: <pub-id pub-id-type="pmid">28892752</pub-id></citation>
</ref>
<ref id="ref45">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tosic</surname> <given-names>J.</given-names></name> <name><surname>Stanojevic</surname> <given-names>Z.</given-names></name> <name><surname>Vidicevic</surname> <given-names>S.</given-names></name> <name><surname>Isakovic</surname> <given-names>A.</given-names></name> <name><surname>Ciric</surname> <given-names>D.</given-names></name> <name><surname>Martinovic</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Graphene quantum dots inhibit T cell-mediated neuroinflammation in rats</article-title>. <source>Neuropharmacology</source> <volume>146</volume>, <fpage>95</fpage>&#x2013;<lpage>108</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.11.030</pub-id>, PMID: <pub-id pub-id-type="pmid">30471296</pub-id></citation>
</ref>
<ref id="ref46">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vilcheze</surname> <given-names>C.</given-names></name> <name><surname>Hartman</surname> <given-names>T.</given-names></name> <name><surname>Weinrick</surname> <given-names>B.</given-names></name> <name><surname>Jain</surname> <given-names>P.</given-names></name> <name><surname>Weisbrod</surname> <given-names>T. R.</given-names></name> <name><surname>Leung</surname> <given-names>L. W.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Enhanced respiration prevents drug tolerance and drug resistance in <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>114</volume>, <fpage>4495</fpage>&#x2013;<lpage>4500</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1704376114</pub-id>, PMID: <pub-id pub-id-type="pmid">28396391</pub-id></citation>
</ref>
<ref id="ref47">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>X. Y.</given-names></name> <name><surname>Lei</surname> <given-names>R.</given-names></name> <name><surname>Huang</surname> <given-names>H. D.</given-names></name> <name><surname>Wang</surname> <given-names>N.</given-names></name> <name><surname>Yuan</surname> <given-names>L.</given-names></name> <name><surname>Xiao</surname> <given-names>R. Y.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>The permeability and transport mechanism of graphene quantum dots (GQDs) across the biological barrier</article-title>. <source>Nanoscale</source> <volume>7</volume>, <fpage>2034</fpage>&#x2013;<lpage>2041</lpage>. doi: <pub-id pub-id-type="doi">10.1039/C4NR04136D</pub-id>, PMID: <pub-id pub-id-type="pmid">25553649</pub-id></citation>
</ref>
<ref id="ref48">
<citation citation-type="other"><person-group person-group-type="author">
<collab id="coll1">World Health Organization</collab>
</person-group> (<year>2022</year>). <source>Global tuberculosis report 2022</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health organization</publisher-name>. Available at: <ext-link xlink:href="https://iris.who.int/bitstream/handle/10665/363752/9789240061729-eng.pdf?sequence=1" ext-link-type="uri">https://iris.who.int/bitstream/handle/10665/363752/9789240061729-eng.pdf?sequence=1</ext-link></citation>
</ref>
<ref id="ref49">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname> <given-names>Z.</given-names></name> <name><surname>Sun</surname> <given-names>Q.</given-names></name> <name><surname>Zhang</surname> <given-names>L.</given-names></name> <name><surname>Kang</surname> <given-names>Z.</given-names></name> <name><surname>Liang</surname> <given-names>L.</given-names></name> <name><surname>Wang</surname> <given-names>Q.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Graphene quantum dot assisted translocation of drugs into a cell membrane</article-title>. <source>Nanoscale</source> <volume>11</volume>, <fpage>4503</fpage>&#x2013;<lpage>4514</lpage>. doi: <pub-id pub-id-type="doi">10.1039/C8NR10091H</pub-id>, PMID: <pub-id pub-id-type="pmid">30806416</pub-id></citation>
</ref>
<ref id="ref50">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>P.</given-names></name> <name><surname>Jiao</surname> <given-names>F.</given-names></name> <name><surname>Wu</surname> <given-names>L.</given-names></name> <name><surname>Kong</surname> <given-names>Z.</given-names></name> <name><surname>Hu</surname> <given-names>W.</given-names></name> <name><surname>Liang</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Molecular dynamics simulation of transport mechanism of graphene quantum dots through different cell membranes</article-title>. <source>Membranes</source> <volume>12</volume>:<fpage>753</fpage>. doi: <pub-id pub-id-type="doi">10.3390/membranes12080753</pub-id></citation>
</ref>
<ref id="ref51">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>X. Y. J.</given-names></name> <name><surname>Peng</surname> <given-names>C.</given-names></name> <name><surname>Hu</surname> <given-names>W.</given-names></name> <name><surname>Zhu</surname> <given-names>Z.</given-names></name> <name><surname>Li</surname> <given-names>W.</given-names></name> <name><surname>Fan</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration</article-title>. <source>Carbon</source> <volume>49</volume>, <fpage>986</fpage>&#x2013;<lpage>995</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.carbon.2010.11.005</pub-id></citation>
</ref>
</ref-list>
</back>
</article>